| 95 | 0 | 43 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探究非小细胞肺癌（NSCLC）患者淋巴结转移的临床病理特征及其与组织β淀粉样蛋白前体蛋白结合蛋白2(APPBP2)、肉豆蔻酰化富含丙氨酸的C激酶底物样蛋白1(MARCKSL1)、肝激酶B1(LKB1)表达水平的关系。方法 以2021年1月至2024年10月山东省立第三医院及山东健康枣庄中心医院收治的548例NSCLC患者为研究对象。结果 肿瘤部位为中央型、肿瘤成分为实性、原发肿瘤直径较大、APPBP2 mRNA表达水平较高、MARCKSL1 mRNA表达水平较高均为NSCLC患者淋巴结转移的危险因素，LKB1阳性为NSCLC患者淋巴结转移的保护因素（P<0.05）。结论 NSCLC患者淋巴结转移的影响因素包括肿瘤部位为中央型、肿瘤成分为实性、原发肿瘤直径较大、APPBP2 mRNA表达水平较高、MARCKSL1 mRNA表达水平较高、LKB1阳性。
Abstract：Objective To explore the clinicopathological features of lymph node metastasis in patients with nonsmall cell lung cancer(NSCLC) and its relationship with the expression levels of β-amyloid precursor protein binding protein 2(APPBP2), myristoylated alanine-rich C kinase substrate-like protein 1(MARCKSL1), and Liver kinase B1(LKB1) in tissues. Methods A total of 548 patients with NSCLC admitted to the Shandong Provincial Third Hospital and Shandong Health Zaozhuang Central Hospital from January 2021 to October 2024 were enrolled as the research subjects. Results Central tumor location, solid tumor component, larger primary tumor diameter, and higher mRNA expression levels of APPBP2 and MARCKSL1 were identified as risk factors for lymph node metastasis in patients with NSCLC. Positive expression of LKB1 was a protective factor against lymph node metastasis in patients with NSCLC(P<0.05). Conclusion The influencing factors of lymph node metastasis in patients with NSCLC include central tumor location, solid tumor component, larger primary tumor diameter, higher mRNA expression levels of APPBP2 and MARCKSL1, and positive expression of LKB1.
[1]王东,徐凤琳,于小涵,等.基于MSCT灌注参数的非小细胞肺癌纵隔淋巴结转移的列线图模型的构建与验证[J].现代肿瘤医学,2023, 31(22):4206-4211.
[2]赵大川,阎石,王亚旗,等. N1期非小细胞肺癌患者肺内转移淋巴结解剖部位与疾病复发风险及预后的关系分析[J].中华医学杂志, 2021, 101(35):2778-2786.
[3] Huang D, Zhao Q, Yang K, et al. CRL2(APPBP2)-mediated TSPYL2degradation counteracts human mesenchymal stem cell senescence[J].Sci China Life Sci, 2024, 67(3):460-474.
[4] Yadav V, Jena M K, Parashar G, et al. Emerging role of microRNAs as regulators of protein kinase C substrate MARCKS and MARCKSL1 in cancer[J]. Exp Cell Res, 2024, 434(2):113891-113891.
[5] Kim J, Lee H M, Cai F, et al. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer[J]. Nat Metab, 2020, 2(12):1401-1412.
[6]中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南（2019版）[J].中华肿瘤杂志, 2020, 42(4):257-287.
[7]张彤,王晓伟,吴俊秀,等. SHOX2和RASSF1A基因甲基化在非小细胞肺癌小活检样本临床病理诊断中的应用价值[J].诊断病理学杂志, 2022, 29(5):389-394.
[8] Seol HY, Kim YS, Kim SJ. Predictive value of 18f-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography for assessment of occult lymph node metastasis in non-small cell lung cancer[J]. Oncology, 2021, 99(2):96-104.
[9]徐鹤,王伟,刘长林,等.临床-影像组学列线图对非小细胞肺癌肺门与纵隔淋巴结转移的预测研究[J].中国CT和MRI杂志,2023, 21(11):84-87.
[10]孙嘉阳,鲁志刚,郭占林,等.老年临床N0期非小细胞肺癌患者术后N1-2期淋巴结转移的危险因素分析[J].中华实用诊断与治疗杂志, 2023, 37(2):129-132.
[11]杨文龙,范懿魏,陆世春,等.直径≤3 cm非小细胞肺癌发生单独N1淋巴结转移的危险因素分析[J].临床肺科杂志, 2023, 28(3):331-335.
[12]赵金龙,田辉,张凤伟.早期非小细胞肺癌淋巴结转移的危险因素研究[J].中国临床医生杂志, 2023, 51(1):20-23.
[13]胡志鹏,冶治,张庆欣.基于能谱CT参数与临床病理因素建立高海拔地区非小细胞肺癌患者的淋巴结转移预测模型[J].实用临床医药杂志, 2022, 26(18):6-10.
[14]刘哲睿,贾晓东,陆荫英.肿瘤坏死因子受体超家族成员21在肝细胞癌中的表达及临床意义[J].临床肿瘤学杂志, 2022, 27(3):201-209.
[15] Ni D, Teng J, Cheng Y, et al. circBIRC6 contributes to the development of non-small cell lung cancer via regulating microRNA-217/amyloid beta precursor protein binding protein 2 axis[J]. Chin Med J(Engl), 2022, 135(6):714-723.
[16]陈丽萍,籍强,陈艳红,等.非小细胞肺癌组织中circBIRC6、APPBP2表达及临床预后意义[J].临床肺科杂志, 2024, 29(5):727-733.
[17] Sheng J, Liu L, Dong T, et al. Circ_SETD3 regulates gefitinib sensitivity and tumor progression by miR-873-5p-dependent regulation of APPBP2 in non-small cell lung cancer[J]. J Chemother, 2022, 34(6):401-413.
[18] Li S, Poon C H, Zhang Z, et al. MicroRNA-128 suppresses tau phosphorylation and reduces amyloid-beta accumulation by inhibiting the expression of GSK3beta, APPBP2, and mTOR in Alzheimer's disease[J].CNS Neurosci Ther, 2023, 29(7):1848-1864.
[19] Li F, Zhao J, Wang L, et al. METTL14-mediated miR-30c-1-3p maturation represses the progression of lung cancer via regulation of MARCKSL1 expression[J]. Mol Biotechnol, 2022, 64(2):199-212.
[20]刘圣娥,栾素梅,胡旺,等.非小细胞肺癌组织的MARCKSL1水平及临床意义[J].临床肿瘤学杂志, 2023, 28(8):740-743.
[21]梅玉洁,赛麦提喀日·阿布都巴日,安恒庆,等.前列腺癌相关基因、癌组织差异表达基因及预后相关基因筛选[J].山东医药,2022, 62(15):12-16.
[22] Jia J, Liu Y, Yang X, et al. IncRNA TYMSOS promotes epithelial-mesenchymal transition and metastasis in thyroid carcinoma through regulating MARCKSL1 and activating the PI3K/Akt signaling pathway[J]. Crit Rev Eukaryot Gene Expr, 2022, 33(1):1-14.
[23] Bian T, Wang Y, Botello J F, et al. LKB1 phosphorylation and deactivation in lung cancer by NNAL, a metabolite of tobacco-specific carcinogen, in an isomer-dependent manner[J]. Oncogene, 2022, 41(33):4042-4054.
基本信息:
中图分类号:R734.2
引用信息:
[1]于琼,姜艳红,门康,等.非小细胞肺癌患者淋巴结转移的临床病理特征及与组织APPBP2、MARCKSL1、LKB1表达水平的关系[J].诊断病理学杂志,2025,32(10):1316-1321.
基金信息:
山东省医药卫生科技发展计划项目（202101041037）
2025-09-24
2025-09-24
2025-09-24